Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: A study in a tuberculosis-endemic country

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kuo, Chih Hsi ^a,b   Lo, Chun Yu ^a   Chung, Fu Tsai ^a   Lee, Kang Yun ^a   Lin, Shu Min ^a   Wang, Chun Hua ^a   Heh, Chih Chen ^a   Chen, Hao Cheng ^b,c   Kuo, Han Pin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b SAINT PAUL S HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; DOCETAXEL; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; TRANSCRIPTION FACTOR FOXP3; TUBERCULOSTATIC AGENT; CXCL10 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN;

AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENDEMIC DISEASE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TAIWAN; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; AGED; ANTIGENS, CD3; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMOKINE CXCL10; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; RECEPTORS, CXCR3; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 84863348587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033226     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Chung FT, Lee KY, Fang YF, Shieh MH, Lin SM, et al. (2011) Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer. Chemotherapy 57: 147-155.
3. Kuo CH, Lin SM, Lee KY, Chung FT, Hsieh MH, et al. (2011) Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 11: 51-56.
4. Burnet FM, (1971) Immunological surveillance in neoplasia. Transplant Rev 7: 3-25.
5. Whiteside TL, (2010) Immune responses to malignancies. J Allergy Clin Immunol 125: S272-283.
6. Ma J, Liu L, Che G, Yu N, Dai F, et al. (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10: 112.
7. Walrath J, Zukowski L, Krywiak A, Silver RF, (2005) Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 33: 48-55.
8. Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA, (2009) T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol 47: 485-492.
9. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, (2010) Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer. BMC Cancer 10: 172.
10. Grange JM, Bottasso O, Stanford CA, Stanford JL, (2008) The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 26: 4984-4990.
11. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, et al. (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124-1127.
12. Stanford JL, Stanford CA, O'Brien ME, Grange JM, (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44: 224-227.
13. Mendes R, O'Brien ME, Mitra A, Norton A, Gregory RK, et al. (2002) Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. Br J Cancer 86: 336-341.
14. Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, et al. (2008) An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 44: 216-223.
15. Kuo CH, Chen HC, Chung FT, Lo YL, Lee KY, et al. (2011) Diagnostic value of EBUS-TBNA for lung cancer with non-enlarged lymph nodes: a study in a tuberculosis-endemic country. PLoS One 6: e16877.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655.
17. Chen YM, Chao JY, Tsai CM, Lee PY, Perng RP, (1996) Shortened survival of lung cancer patients initially presenting with pulmonary tuberculosis. Jpn J Clin Oncol 26: 322-327.
18. Solak O, Sayar A, Metin M, Erdogu V, Cuhadaroglu S, et al. (2005) The coincidence of mediastinal tuberculosis lymphadenitis in lung cancer patients. Acta Chir Belg 105: 180-182.
19. Cicenas S, Vencevicius V, (2007) Lung cancer in patients with tuberculosis. World J Surg Oncol 5: 22.
20. Tamura A, Hebisawa A, Sagara Y, Suzuki J, Masuda K, et al. (2005) [Coexistence of lung cancer and active pulmonary mycobacteriosis]. Kekkaku 80: 413-419.
21. Grange JM, Stanford JL, Stanford CA, (2002) Campbell De Morgan's 'Observations on cancer', and their relevance today. J R Soc Med 95: 296-299.
22. Dalgleish AG, Whelan MA, (2006) Cancer vaccines as a therapeutic modality: The long trek. Cancer Immunol Immunother 55: 1025-1032.
23. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, et al. (2009) Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14: 909-920.
24. Augustin A, Kubo RT, Sim GK, (1989) Resident pulmonary lymphocytes expressing the gamma/delta T-cell receptor. Nature 340: 239-241.
25. Huygen K, Van Vooren JP, Turneer M, Bosmans R, Dierckx P, et al. (1988) Specific lymphoproliferation, gamma interferon production, and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand J Immunol 27: 187-194.
26. Okamoto M, Hasegawa Y, Hara T, Hashimoto N, Imaizumi K, et al. (2005) T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. Chest 128: 4030-4035.
27. Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, et al. (2010) Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 136: 35-45.
28. Talmadge JE, (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13: 5243-5248.
29. Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD, (2009) Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 182: 2795-2807.
30. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, et al. (2008) Regulation of alternative macrophage activation by galectin-3. J Immunol 180: 2650-2658.